Critical prognostic value of the log odds of negative lymph nodes/tumor size in rectal cancer patients

Abstract

BACKGROUND

The number of negative lymph nodes (NLNs) and tumor size are associated with prognosis in rectal cancer patients undergoing surgical resection. However, little is known about the prognostic significance of the NLN count after adjusting for tumor size.

AIM

To assess the prognostic impact of the log odds of NLN/tumor size (LONS) in rectal cancer patients.

METHODS

Data of patients with stage I–III rectal cancer were extracted from the Surveillance, Epidemiology, and End Results Program database. These patients were randomly divided into a training cohort and a validation cohort. Univariate and multivariate Cox regression analyses were used to determine the prognostic value of the LONS. The optimal cutoff values of LONS were calculated using the "X-tile" program. Stratified analysis of the effect of LONS on cancer-specific survival (CSS) and overall survival (OS) were performed. The Kaplan-Meier method with the log-rank test was used to plot the survival curve and compare the survival data among the different groups.

RESULTS

In all, 41080 patients who met the inclusion criteria were randomly divided into a training cohort (n = 28775, 70%) and a validation cohort (n = 12325, 30%). Univariate and multivariate analyses identified the continuous variable LONS as an independent prognostic factor for CSS [training cohort: Hazard ratio (HR) = 0.47, 95% confidence interval (CI): 0.44–0.51, P < 0.001; validation cohort: HR = 0.46, 95%CI: 0.41-0.52, P < 0.001] and OS (training cohort: HR = 0.53, 95%CI: 0.49-0.56, P < 0.001; validation cohort: HR = 0.52, 95%CI: 0.42-0.52, P < 0.001). The X-tile program indicated that the difference in CSS was the most significant for LONS of -0.8, and the cutoff value of -0.4 can further distinguish patients with a better prognosis in the high LONS group. Stratified analysis of the effect of the categorical variable LONS on CSS and OS revealed that LONS was also an independent predictor, independent of pN stage, pT stage, tumor-node-metastasis stage, site, age, sex, the number of examined lymph nodes, race, preoperative radiotherapy and carcinoembryonic antigen level.

CONCLUSION

LONS is associated with improved survival of rectal cancer patients independent of other clinicopathological factors.

Key Words: Rectal cancer; Negative lymph nodes; Negative lymph nodes/tumor size; Prognosis; Survival analysis; Surveillance, Epidemiology, and End Results Program

Core Tip: Log odds of negative lymph nodes/tumor size (LONS) was defined as the log of the ratio between negative lymph node count and the tumor size and has been first reported as a survival predictive tool in our study. Univariate and multivariate analyses confirmed LONS as an independent prognostic factor for stage I to III rectal cancer. The X-tile program demonstrated that the optimal cutoff was -0.8. Stratified analysis and Kaplan-Meier curves showed a significant improvement in the 10-year cancer-specific survival and overall survival in the high LONS group independent of clinicopathological factors.

INTRODUCTION

Rectal cancer (RC) is a common digestive tract tumor. Currently, it is the world's fourth most deadly cancer with almost 900000 deaths annually. Although Western developed countries exhibit a slightly or steady declining trend, the morbidity and mortality of colorectal cancer (CRC) in developing countries, such as China, are also rapidly increasing[1]. Treatment options for CRC have been developed rapidly in the past 20 years; however, surgery is still the cornerstone of curative intent treatment[2]. Of course, postoperative adjuvant radiotherapy and/or chemotherapy in high-risk patients can improve the long-term survival rates[3]; unfortunately, due to the lack of reliable markers, selecting the optimal therapy for individuals is challenging for clinicians[4]. Presently, the most widely used model for risk stratification in CRC is tumor-node-metastasis (TNM) staging. The American Joint Committee on Cancer (AJCC) recommends postoperative adjuvant chemotherapy for patients with high-risk stage II and stage III; however, heterogeneity in prognosis still exists in patients with the same TNM stage[4].

In recent years, biomarkers, such as the number of examined lymph nodes (LNs)[5], negative LNs (NLNs)[6], tumor size[7] and epigenetic biomarkers[8] have increasingly demonstrated independent prognostic value in RC. Among these biomarkers, except for the examined LNs (ELNs) and NLNs that can reflect the degree of lymph node dissection (LND) in surgery, the others mainly represent tumor characteristics or the patient's state. Unfortunately, most of these biomarkers are expensive and difficult to measure. Therefore, to individualize treatment strategies and for clinical application convenience, more prognostic factors should be identified from daily medical records.

The presence of lymph node metastasis is an important prognostic factor for CRC patients. Some studies have revealed that the more ELNs[8] or NLNs[6] that are removed, the fewer LN micrometastases that are missed, and these biomarkers are independent prognostic factors in gastric cancer[9], RC[6], lung cancer[10], and others. However, the number of lymph nodes that can be retrieved varies with the age and sex of the patient and on the tumor grade or site[11], and the skills of the surgeons[12]. Therefore, the same ELNs and NLNs do not mean the same level of LND.

As one of the tumor burden markers, tumor size is defined as the maximal horizontal tumor diameter and has been confirmed to be a prognostic indicator for some solid tumors, including CRC[7,13-15]. Using tumor size to adjust and improve the prognostic value of tumor markers is a novel and common approach, and has been used for carcinoembryonic antigen (CEA)[16] and prostate specific antigen density[17]. Whether the combination of tumor size and NLNs serves as a novel prognostic marker for RC remains unknown.

In the current study, we considered the value of NLNs/tumor size as non-lognormal distribution data, and zero NLN as no logarithm. Therefore, we defined the log odds of negative lymph nodes/tumor size (LONS) as the log of the ratio between the NLN counts plus one and the tumor size, which reflects the NLNs adjusted by the tumor size, to better represent the degree of LND. Our aim was to investigate the prognostic value of LONS in patients with RC.

MATERIALS AND METHODS

Patients

The Surveillance, Epidemiology, and End Results Program (SEER) collects and provides information on cancer patients such as demographics, tumor characteristics (histology, grading, and TNM stage), treatment and vital status, covering 27.8% of the population in the United States.

Information on patients who were diagnosed with stage I to III RC and underwent a radical excision were collected from the 18 Researcher data (with additional treatment fields) using SEER*stat 8.3.8 software, which was submitted in November 2018. According to the histological types, including adenocarcinoma (8140/3), mucinous adenocarcinoma (8480/3), and signet-ring cell carcinoma (8490/3), we identified a total of 93496 primary RC patients diagnosed between 2004 and 2015. Only those patients between 18 and 85 years at diagnosis were enrolled.

The exclusion criteria were as follows: (1) The tumor size was unknown; (2) Unclear ELNs and NLNs; (3) The T stage or N stage or M stage was unknown; (4) The survival time was 0 mo; and (5) There was no surgical resection or the case lacked a detailed description of the surgery. Patients who satisfied the inclusion criteria were randomly divided into two cohorts (7:3) for cross-validation: A training cohort and a validation cohort. The training cohort was used to generate an optimal cutoff point, and the validation cohort was used to test the applicability of this cutoff point and the final model. Due to the strict register-based nature of the study, informed consent was waived. Moreover, the study was exempted from Institutional Review Board approval, in view of the SEER’s use of unidentifiable patient information.

Data collection

Parameters, including preoperative radiation and chemotherapy status, the exact tumor size, regional nodes examined, regional nodes positive, tissue type, tumor differentiation, tumor deposits, CEA levels, survival status, and demographic characteristics were collected. The TNM status of each patient was re-evaluated according to the 8^th edition of the AJCC Cancer Staging Manual based on the tumor size, local extension, and LN involvement recorded in the SEER database. Cancer-specific deaths were treated as events. Causes of death that were unclear or deaths from other causes were treated as censored observations. The latest follow-up date occurred in November 2018.

Statistical analysis

In our study, the value of the NLNs/size includes non-lognormal distribution data and the zero NLN had no logarithm. Therefore, the data were logarithmically transformed by NLN counts plus one to obtain approximately normal frequency distributions. Continuous and categorical variables were expressed as medians and totals (percentages), respectively. Univariate Cox proportional hazards regression was performed to identify potential prognostic factors. Variables with a P < 0.10 in the univariate analysis were selected to include in the multivariate Cox model. Multivariate analysis using the Cox proportional hazards regression model was used to identify independent risk factors and to calculate each hazard ratio (HR). Stratified analyses of the LONS effect on cancer-specific survival (CSS) and overall survival (OS) rates based on different clinicopathological factors were performed by Cox proportional hazards regression. The optimal cutoff values of the LONS were calculated by the X-tile program in terms of CSS[18]. Based on this cutoff, we divided the patients into two groups: The high LONS group and low LONS group. The Kaplan-Meier method with the log-rank test was used to plot the survival curves and compare the survival data among the different groups. All tests were bilateral, and P < 0.05 was considered statistically significant. All analyses were performed using SPSS 22.0. The primary outcome was CSS. The secondary endpoint was OS.

RESULTS

Baseline characteristics

A total of 93496 patients with primary RC from 2004 to 2015 were identified in the SEER database. Among them, 30795 did not undergo surgical resection or detailed surgical information was lacking, 52 were not histologically confirmed to have adenocarcinoma, and for 10120 patients, their record failed to include the exact tumor size. Of the remaining 52529 patients, 2597 patients were excluded due to no LNs removed or unclear ELNs or PLNs, 6791 patients were not classified as stage I to III, 1734 patients were not between 18 and 85 years of age, and 327 had missing survival time information. After excluding these patients, 41080 patients satisfied the inclusion criteria (Figure 1). The final cases were randomly divided into the training cohort (n = 28775, 70%) and the validation cohort (n = 12325, 30%).

Figure 1 Flowchart of patient selection. SEER: Surveillance, Epidemiology, and End Results Program; ELNs: Examined lymph nodes; PLNs: Positive lymph nodes.

Among these patients, the median (interquartile range) age, tumor size, ELN count, and NLN count were 62 (53-72) years old, 40 (27-55) mm, 14 (10-20), and 13 (9-18), respectively. In total, 16998 (59.1%) patients were male, 11757 (40.1%) were female. A total of 18661 (64.9%) tumors were located in the rectum, and 10094 (35.1%) were located in the rectosigmoid junction. In addition, 10385 (36.1%) and 17688 (61.5%) patients received preoperative radiotherapy and chemotherapy, respectively. The proportions of N0, N1 and N2 stage were 61.3%, 25.3% and 13.3%, respectively. A similar distribution of features was observed in patients in the validation cohort. Detailed information on the clinical pathological features is shown in Table 1.

Table 1 Baseline clinicopathological features of patients in the training cohort and validation cohort.

Feature	Training cohort (n = 28875)	Validation cohort (n = 12325)
	n (%)	n (%)
Median age (IQR), yr	62 (53-72)	62 (53-71)
Median tumor size (IQR) mm	40 (27-55)	40 (26-55)
Median ELN count (IQR)	14 (10-20)	15 (10-20)
Median NLN count (IQR)	13 (9-18)	13 (9-18)
Median LONS (IQR)	-0.44 (-0.66 to -0.24)	-0.44 (-0.65 to -0.22)
Sex
Male	16998 (59.1)	7262 (58.9)
Female	11757 (40.9)	5063 (41.1)
TNM stage
I	7280 (25.3)	3132(25.4)
II	10355 (36.0)	4662 (36.2)
III	11120 (38.7)	4731 (38.4)
Differentiation
Poor	3741 (13.0)	1606 (13.0)
Moderate	21590 (75.1)	9169 (74.4)
High	2032 (7.1)	893 (7.2)
Unknown	1392 (4.8)	657 (5.3)
Preoperative radiotherapy
Yes	10385 (36.1)	4419 (35.9)
No	18730 (63.9)	7906 (64.1)
Chemotherapy
Yes	17688 (61.5)	7501 (60.9)
No	11067 (38.5)	4824 (39.1)
CEA
Normal	1056 (38.4)	4712(38.5)
High	6676 (23.2)	1736 (16.0)
Unknown	11023 (38.3)	4924 45.5)
N stage
N0	17635 (61.3)	7594 (61.6)
N1	7288 (25.3)	3036 (24.9)
N2	3832 (13.3)	1668 (13.5)
Histology type
Adenocarcinoma	27233 (94.7)	11640 (94.4)
MAC and SRCC	1522 (5.3)	5.6 (13.5)
Location
Rectum	18661 (64.9)	8044 (65.3)
Rectosigmoid junction	10094 (35.1)	4281 (34.7)
Race
White	23264 (80.9)	9962 (81.1)
Black	2357 (8.2)	1028 (8.3)
Others	3062 (10.6)	1299 (10.5)

CEA: Carcinoembryonic antigen; ELNs: Examined lymph nodes; IQR: Interquartile range; LONS: Log odds of negative lymph nodes/tumor size; MAC: Mucinous adenocarcinoma; NLNs: Negative lymph nodes; SRCC: Signet-ring cell carcinoma; TNM: Tumor-node-metastasis.

Univariate and multivariate analysis

Age, sex, location, race, TNM stage, tumor size, differentiation, histology type, preoperative radiotherapy, chemotherapy, preoperative CEA and LONS were identified as potential prognostic factors by univariate analysis for CSS (Table 2) and OS (Supplementary Table 1) in both cohorts. The HR showed an obvious improvement for LONS [0.330, 95% confidence interval (CI): 0.308-0.354], which was the NLNs adjusted by the tumor size, compared with the NLNs (0.971, 95%CI: 0.967-0.974) in CSS. Similar results were confirmed for the OS. Multivariate analysis with Cox regression for CSS (Table 3) and OS (Supplementary Table 2) in both cohorts were performed. All of these factors with the exception of tumor size were independent prognostic factors for RC. Similar results were observed in patients from the validation cohort.

Table 2 Univariate analysis of prognostic factors for cancer-specific survival.

Variable	Training cohort (n = 28755)			Validation cohort (n = 12325)
	HR	95%CI	P value	HR	95%CI	P value
Age1	1.022	1.019-1.024	< 0.001	1.021	1.018-1.025	< 0.001
Tumor size1	1.004	1.003-1.004	< 0.001	1.003	1.002-1.003	< 0.001
NLNs1	0.971	0.967-0.974	< 0.001	0.970	0.964-0.975	< 0.001
LONS1	0.330	0.308-0.354	< 0.001	0.331	0.298-0.367	< 0.001
Sex (ref = male)	0.887	0.840-0.937	< 0.001	0.901	0.829-0.979	< 0.001
TNM (ref = stage III)
I	0.226	0.207-0.247	< 0.001	0.235	0.206-0.269	< 0.001
II	0.482	0.454-0.512	< 0.001	0.486	0.443-0.532	< 0.001
Differentiation (ref = G3 + G4)
G1	0.436	0.382-0.497	< 0.001	0.424	0.348-0.517	< 0.001
G2	0.573	0.536-0.613	< 0.001	0.566	0.511-0.626	< 0.001
Unknown	0.532	0.459-0.616	< 0.001	0.515	0.415-0.641	< 0.001
Histology (ref = MAC and SRCC)	0.537	0.488-0.590	< 0.001	0.531	0.462-0.612	< 0.001
Preoperative RT (ref = Yes)	0.884	0.836-0.934	< 0.001	0.938	0.861-1.020	0.135
Chemotherapy (ref = Yes)	0.746	0.705-0.790	< 0.001	0.776	0.712-0.845	< 0.001
Location (ref = rectum)	1.134	1.072-1.200	< 0.001	1.177	1.079-1.284	< 0.001
Race (ref = others)
White	1.045	0.955-1.143	0.336	1.013	0.883-1.162	0.853
Black	1.435	1.275-1.616	< 0.001	1.465	1.225-1.753	< 0.001
CEA (ref = High)
Normal	0.546	0.510-0.584	< 0.001	0.498	0.448-0.553	< 0.001
Unknown	0.684	0.641-0.729	< 0.001	0.686	0.622-0.756	< 0.001

¹These variables were treated as continuous data.

CI: Confidence interval; CEA: Carcinoembryonic antigen; HR: Hazard ratio; LONS: Log odds of negative lymph nodes/tumor size; MAC: Mucinous adenocarcinoma; NLNs: Negative lymph nodes; RT: Radiotherapy; SRCC: Signet-ring cell carcinoma; TNM: Tumor-node-metastasis.

Table 3 Multivariate analysis of prognostic factors for cancer-specific survival.

Variable	Training cohort (n = 28755)			Validation cohort (n = 12325)
	HR	95%CI	P2 value	HR	95%CI	P2 value
Age (ref: ≤ 60 years old)	1.54	1.46-1.63	< 0.001	1.50	1.37-1.62	< 0.001
Tumor size1	1.00	1.00-1.00	0.637	1.00	1.00-1.00	0.987
LONS1	0.47	0.44-0.51	< 0.001	0.46	0.41-0.52	< 0.001
Sex (ref = male)	0.90	0.85-0.95	< 0.001	0.91	0.83-0.99	0.021
TNM1 (ref = stage III)
I	0.28	0.22-0.26	< 0.001	0.264	0.23-0.31	< 0.001
II	0.47	0.45-0.51	< 0.001	0.50	0.46-0.55	< 0.001
Differentiation (ref = G3 + G4)
G1	0.63	0.56-0.72	< 0.001	0.60	0.49-0.73	< 0.001
G2	0.72	0.67-0.77	< 0.001	0.71	0.62-0.82	< 0.001
Unknown	0.63	0.54-0.73	< 0.001	0.63	0.51-0.79	< 0.001
Histology (ref = MAC and SRCC)	0.78	0.71-0.86	< 0.001	0.71	0.62-0.82	< 0.001
Preoperative RT (ref = Yes)	0.90	0.85-0.96	< 0.001	0.92	0.83-1.03	0.147
Chemotherapy (ref = Yes)	1.42	1.32-1.52	< 0.001	1.36	1.22-1.51	< 0.001
Location (ref = rectum)	0.82	0.77-0.87	< 0.001	0.77	0.70-0.85	< 0.001
Race (ref = others)
White	1.10	1.00-1.20	0.043	1.04	0.91-1.20	0.555
Black	1.45	1.29-1.63	< 0.001	1.49	1.25-1.79	< 0.001
CEA (ref = High)
Normal	0.66	0.62-0.71	< 0.001	0.60	0.54-0.67	< 0.001
Unknown	0.80	0.75-0.85	< 0.001	0.77	0.7-0.86	< 0.001

¹These variables were treated as continuous data.

²P values were adjusted for sex, age, race, tumor-node-metastasis stage, location, preoperative radiotherapy, carcinoembryonic antigen, differentiation and chemotherapy as covariates.

CI: Confidence interval; CEA: Carcinoembryonic antigen; HR: Hazard ratio; LONS: Log odds of negative lymph nodes/tumor size; MAC: Mucinous adenocarcinoma; SRCC: Signet-ring cell carcinoma; RT: Radiotherapy; TNM: Tumor-node-metastasis.

Optimal cutoff values of LONS and Kaplan-Meier curves

The "X-tile" program was then used to obtain the optimal cutoff values of LONS, and the highest chi-square log-rank value of 613.1 was produced in terms of CSS when applying -0.8 as the cutoff value of LONS. This cutoff divided the LONS into the high LONS group and the low LONS group. Kaplan-Meier curves revealed a significant improvement in the 10-year CSS (Figure 2A) and OS (Figure 2B) in the high LONS group compared with the low LONS group in the training cohort. The better outcomes of those with a high LONS was confirmed in the validation cohort as these patients exhibited a better 10-year CSS (Figure 3A) and OS (Figure 3B).

Figure 2 Kaplan-Meier survival curves of the cutoff values in the training cohort. A: Kaplan Meier survival curve of cutoff -0.8 cancer-specific survival in the training cohort; B: Kaplan Meier survival curve of cutoff -0.8 overall survival in the training cohort; C: Kaplan Meier survival curve of cutoff -0.9 and -0.4 cancer-specific survival in the training cohort; D: Kaplan Meier survival curve of cutoff -0.9 and -0.4 overall survival in the training cohort.

Figure 3 Kaplan-Meier survival curves of cutoff values in the validation cohort. A: Kaplan Meier survival curve of cutoff -0.8 cancer-specific survival in the validation cohort; B: Kaplan Meier survival curve of cutoff -0.8 overall survival in the validation cohort; C: Kaplan Meier survival curve of cutoff -0.9 and -0.4 cancer-specific survival in the validation cohort; D: Kaplan Meier survival curve of cutoff -0.9 and -0.4 overall survival in the validation cohort.

Moreover, the cutoff values of -0.9 and -0.4 also had discriminatory power for different prognoses with a maximum of the chi-square log-rank value of 845.3. This cutoff divided the LONS into three subsets, the 10-year CCS (Figure 2C) and OS (Figure 2D) differed for the high, middle and low group. The statistical results of the validation cohort were consistent with those of the training cohort, and the 10-year CCS (Figure 3C) and OS (Figure 3D) were different for the high, middle and low groups.

Stratified analysis of the LONS effect on CSS and OS rates based on the different clinicopathological factors

To confirm the independent prognostic effect of LONS on the different clinicopathological factors, the role of LONS on CSS and OS were further studied by stratified analysis with a multivariate Cox proportional hazards model. Among the subsets of the pN stage, pT stage, and TNM stage, sex, age, location, preoperative radiotherapy, CEA, ELNs, differentiation and chemotherapy but not pT4b, N1c and G1, LONS were significantly associated with CSS as categorical variables in the training cohort, and the HR increased strikingly with the increment of ELNs and degree of differentiation (Table 4, reference was the high LONS group). For OS, only in the subgroup of N1c (Supplementary Table 3), LONS was not an independent prognostic factor. Similar results were obtained in the validation group cohort. However, Kaplan-Meier curves of pT, pN and pTNM, including pT4b, pN1c and G1, revealed that a higher LONS was significantly correlated with improved CSS (Figures 4 and 5) and OS (Supplementary Figure 1) in each subset. The validation cohort showed similar results (Supplementary Figures 2 and 3).

Figure 4 Kaplan-Meier survival curves of T stage and N stage subgroups for cancer-specific survival in the training cohort.

Figure 5 Kaplan-Meier survival curves of tumor-node-metastasis stage subgroup for cancer-specific survival and overall survival in the training cohort.

Table 4 Multivariate analyses for evaluating log odds of negative lymph nodes/tumor size effect on cancer-specific survival based on different clinicopathological factors¹.

Variable	Training cohort (n = 28755)			Validation cohort (n = 12325)
	HR	95%CI	P2 value	HR	95%CI	P2 value
All	1.673	1.57-1.78	< 0.001	1.715	1.56-1.86	< 0.001
N stage
N0	1.53	1.37-1.71	< 0.001	1.422	1.20-1.68	< 0.001
N1a	1.49	1.24-1.78	< 0.001	1.73	1.26-2.36	0.001
N1b	1.42	1.21-1.65	< 0.001	1.61	1.28-2.04	< 0.001
N1c	1.68	0.96-2.92	0.069	2.12	0.98-4.60	0.057
N2a	1.64	1.40-1.93	< 0.001	1.7	1.33-2.18	< 0.001
N2b	1.55	1.34-1.79	< 0.001	1.37	1.10-1.71	0.005
T stage
T1	1.69	1.47-1.95	< 0.001	1.96	1.19-3.22	0.008
T2	1.42	1.16-1.73	0.001	1.6	1.18-2.16	0.003
T3	1.63	1.56-1.80	< 0.001	1.653	1.48-1.85	< 0.001
T4a	1.51	1.18-1.94	0.001	1.64	1.12-2.40	0.011
T4b	1.22	0.97-1.53	0.084	1.52	1.04-2.21	0.03
TNM stage
I	1.68	1.54-1.87	< 0.001	1.59	1.13-2.23	0.007
II	1.55	1.37-1.75	< 0.001	1.36	1.12-1.65	0.002
III	1.73	1.60-1.87	< 0.001	1.79	1.60-2.02	< 0.001
Sex
Male	1.722	1.59-1.86	< 0.001	1.715	1.52-1.94	< 0.001
Female	1.588	1.44-1.76	< 0.001	1.715	1.47-1.99	< 0.001
Age, yr
≤ 60	1.884	1.71-2.08	< 0.001	1.936	1.67-2.25	< 0.001
> 60	1.554	1.44-1.68	< 0.001	1.598	1.42-1.80	< 0.001
Differentiation
G1	1.268	0.94-1.72	0.125	1.549	1.03-2.33	0.035
G2	1.62	1.50-1.75	< 0.001	1.678	1.49-1.89	< 0.001
G3	1.967	1.73-2.23	< 0.001	1.859	1.53-2.26	< 0.001
Location
Rectum	1.647	1.53-1.77	< 0.001	1.613	1.44-1.81	< 0.001
Rectosigmoid junction	1.73	1.55-1.93	< 0.001	2.018	1.70-2.39	< 0.001
CEA
High	1.735	1.56-1.93	< 0.001	1.761	1.50-2.07	< 0.001
Normal	1.701	1.52-1.91	0	1.7	1.42-2.02	0
Preoperative RT
Yes	1.522	1.38-1.68	< 0.001	1.42	1.22-1.66	< 0.001
No	1.782	1.65-1.93	< 0.001	1.92	1.70-2.16	< 0.001
Chemotherapy
Yes	1.68	1.56-1.81	< 0.001	1.662	1.49-1.86	< 0.001
No	1.62	1.44-1.82	< 0.001	1.774	1.49-2.11	< 0.001
ELNs
0-10	1.415	1.29-1.56	< 0.001	1.439	1.24-1.67	< 0.001
11-20	1.79	1.61-2.00	< 0.001	2.10	1.78-2.48	< 0.001
> 20	3.30	2.64-4.14	< 0.001	2.61	1.83-3.70	< 0.001

¹Log odds of negative lymph nodes/tumor size was treated as categorical variable, and the high group as reference.

²P values were adjusted for sex, age, race, tumor-node-metastasis stage, location, preoperative radiotherapy, carcinoembryonic antigen, differentiation and chemotherapy as covariates.

CI: Confidence interval; CEA: Carcinoembryonic antigen; HR: Hazard ratio; RT: Radiotherapy; TNM: Tumor-node-metastasis; ELNs: Examined lymph nodes.

DISCUSSION

In the present study, the large population-based SEER database was first used to quantify the relative degree of LND and to evaluate the prognostic value of LONS for stage I to III RC. Our results demonstrated that high LONS was associated with improved survival of RC patients. Subgroup analysis confirmed that LONS was an independent prognostic factor independent of the clinicopathological factors.

Previous studies suggested that ELN[11] and NLN[6] were correlated with survival of RC independent of lymph node metastasis and tumoral molecular alterations. In addition, the greater the number of negative lymph nodes, the better the level of LND was. However, given that the number of lymph nodes that can be retrieved varies by age and sex of the patient, the tumor grade or site, and the skills of the surgeons and that NLN lacks information about the biological characteristics of the tumors, the value of NLN in survival prediction remains underappreciated. Thus, NLN exhibits limitations in clinical applications, and consensus about its utility is lacking in the literature.

As one of the major tumor characteristics, tumor size is not only related to the prognosis[7], but also closely related to its biological characteristics[19]. Therefore, we decided to use LONS, which is defined as the log of the ratio between the number of negative nodes plus one and the tumor size and serves as the index of the average number of NLNs per tumor unit. The higher the value, the more negative lymph nodes that were obtained. Conversely, a lower LONS value indicates fewer NLNs per tumor unit. Therefore, LONS can be used to compare the relative level of LND among different patients.

In our study, univariate analyses indicated that the HR of NLNs was 0.971 (95%CI: 0.967-0.974), and the HR of NLNs adjusted by tumor size was 0.330 (95%CI: 0.308-0.354). Our results revealed that using tumor size to adjust NLNs may significantly improve the prognostic value of NLNs. We confirmed the independent prognostic value of LONS among all patients with stage I–III RC by multivariate Cox analysis and in a validation cohort. A LONS cutoff value of -0.8 divided patients into the high LONS group and the low LONS group. Kaplan-Meier curves showed that patients with a high LONS (over -0.8) had a significantly better 10-year CSS and OS. A more encouraging result was that a cutoff value of -0.4 can further distinguish patients with a better prognosis in the high LONS group. Thus, postoperative LONS can be applied as a novel prognostic marker for patients with stage I–III RC.

Notably, to confirm the independent prognostic effect of LONS, we stratified the analysis of the LONS effect on the CSS and OS rates based on different clinicopathological factors, including CEA level, preoperative radiotherapy and chemotherapy, age, sex, location, differentiation, histology type, the number of ELNs, TNM stage, pT stage and pN stage. Excitingly, this study demonstrated that LONS was associated with improved survival of RC patients independent of their clinicopathological factors, and the HR increased strikingly with the increment of ELNs and degree of differentiation. Even N0 stage patients with a poor prognosis can be distinguished from these patients, who are generally considered to have a good outcome using LONS. Although there was no significant difference in T4b, N1c or the G1 subsets in the multivariate Cox analysis, survival analysis still demonstrated that patients with high LONS exhibited a better survival benefit. These results suggested that LONS is an independent prognostic factor that is independent of tumor characteristics and can be used as an index of relative LND. This marker can be simply calculated from the postoperative pathological report, at no extra cost. With widespread clinical use, additional improvements in the accuracy of predicting 10-year outcomes will benefit more patients. Special attention should be given to lower LONS patients with stage I and no high-risk stage IIa tumors that may be underestimated as stage I or II due to insufficient LND. These patients should undergo early clinical interventions. For stage III patients with a lower LONS, systematic and intensive treatment should be given more actively to achieve the same therapeutic effect.

However, we admit that there were some inherent limitations in our study. First, using tumor size to represent tumor characteristics is not precise because the histological type, differentiation degree and genotyping of RC are also important biological characteristics that are not included in our adjustment factors. In addition, the tumor size cannot represent the actual tumor volume or tumor load[20]; however, tumor size is closely related to tumor grade[15], tissue differentiation[21] and other biological characteristics[22]. For clinical application, tumor size represents a convenient and quick method that can be applied to roughly estimate the tumor volume[16]. Second, beyond tumor size, NLNs are also related to the above factors, that are not included in the adjustment scope of this study and may affect the judgment of the degree of LND. Third, due to the retrospective nature of the SEER, selection bias could not be completely avoided. Furthermore, our results were not validated in an external database. Whether LONS is truly associated with CSS and OS requires further study.

CONCLUSION

In summary, patients with high LONS have a better outcome than those with low LONS. LONS is an independent prognostic factor that is independent of clinicopathological features and can be used as a relative index for the degree of LND. LONS can be used as a novel marker for risk stratification and therapeutic decision-making in RC patients after surgery.

ARTICLE HIGHLIGHTS

Research background

Rectal cancer (RC) is the world's fourth most deadly cancer with almost 900000 deaths annually. Therapy options for RC have been developed rapidly in the past decade, postoperative adjuvant radiotherapy and/or chemotherapy in high-risk patients can improve their long-term survival rates; however, the clinical outcomes among RC patients with the same tumor-node-metastasis (TNM) stage might be completely different. Unfortunately, due to the lack of reliable markers, selecting the optimal therapy for individuals is challenging for clinicians.

Research motivation

The degree of lymph node dissection (LND) is closely related to the prognosis of RC; however, so far, there is no objective and effective evaluation index for LND. Previous studies have suggested that examined lymph nodes (ELNs), negative lymph nodes (NLNs) and size were closely related to the prognosis of RC. Other studies have added another factor such as tumor size to improve the prognostic value of biomarkers, for example preoperative serum carcinoembryonic antigen (CEA) and prostate-specific antigen density. Therefore, we defined a novel prognostic score, the log odds of NLN/tumor size (LONS), as the log of the ratio between the NLN counts plus one and the tumor size, which reflects the NLNs adjusted by the tumor size, to better represent the degree of LND.

Research objectives

Our aim was to assess a potentially novel prognostic score to stratify risks for RC patients. At the same time, we also aimed to investigate whether LONS can distinguish different pathological stages and clinical features, to better guide the treatment strategies and follow-up plan.

Research methods

The data of stage I–III RC patients were extracted from the Surveillance, Epidemiology, and End Results Program (SEER) database from 2004 to 2015. Univariate and multivariate Cox regression analyses were applied to determine the prognostic impact of the LONS. The optimal cutoff values of the LONS were calculated using the "X-tile" program. Stratified analysis of the LONS effect on cancer-specific survival (CSS) and overall survival (OS) were performed. The Kaplan-Meier method with the log-rank test was used to plot the survival curve and compare the survival data among the different groups.

Research results

In all, 41080 patients were finally included in the study and randomly divided into a training cohort (n = 28775, 70%) and a validation cohort (n = 12325, 30%). Univariate and multivariate analyses identified the continuous variable LONS as an independent prognostic factor for CSS and OS. The X-tile program indicated that the difference in CSS was the most significant for LONS of -0.8, and the cutoff value of -0.4 can further distinguish patients with a better prognosis in the high LONS group. Stratified analysis of the effect of the categorical variable LONS on CSS and OS revealed that LONS was also an independent predictor independent of pN stage, pT stage, TNM stage, site, age, sex, the number of ELNs, race, preoperative radiotherapy and CEA level.

Research conclusions

Patients with high LONS have a better outcome than those with low LONS. LONS is an independent prognostic factor that is independent of clinicopathological features and can serve as a relative index for the degree of LND. LONS can be used as a novel marker for risk stratification and therapeutic decision-making in RC patients after surgery.

Research perspectives

Due to the retrospective nature of the SEER database, we cannot obtain high-level clinical evidence, but our study provides a novel approach for the evaluation of LND and suggests a potentially novel prognostic score to stratify risks for RC patients at the same stage.